Rhea-AI Summary
Liminal BioSciences Inc. (NASDAQ: LMNL) updated its 2020 guidance regarding key milestones amid the COVID-19 pandemic. The company plans to re-submit its biologics licensing application (BLA) for Ryplazim® to the FDA in Q3 2020 and initiate a Phase 1 clinical trial for fezagepras in the second half of 2020. CEO Kenneth Galbraith reaffirmed their commitment to advancing their business during these uncertain times. Liminal BioSciences specializes in developing treatments for fibrosis-related diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
111.02%
Tags